Living Donor Versus Deceased Donor Liver Transplantation for HCC.

Abstract readReview

In one paragraph

Review in Journal of gastrointestinal cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Metagenomic Next-Generation Sequencing Versus Traditional Laboratory Methods for the Diagnosis and Treatment of Infection in Liver Transplantation.Frontiers in cellular and infection microbiology · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sait Murat DoğanDepartment of Surgery and Liver Transplantation Institute, İnönü University Faculty of Medicine, Elazığ yolu 10.km, 44280, Malatya, Turkey. saitmuratdogan@hotmail.com.ORCID https://orcid.org/0000-0001-8840-4365

Koray KutlutürkDepartment of Surgery and Liver Transplantation Institute, İnönü University Faculty of Medicine, Elazığ yolu 10.km, 44280, Malatya, Turkey.ORCID https://orcid.org/0000-0002-7030-4953

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLiver transplantation is the definitive treatment modality of the patients having an end-stage liver disease with hepatocellular carcinoma. DISCUSSION: The number of living donor liver transplantations has been increased because of the deceased donor organ shortage, especially in Asian countries.

conclusionReports of different clinics about the postoperative course and tumor recurrence rates comparing living donor versus deceased donor liver transplantations, besides patient selection criteria, are reviewed along with our clinic's experiences.

Indexed as

AllograftsCarcinoma, HepatocellularEnd Stage Liver DiseaseFollow-Up StudiesHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationLiving DonorsNeoplasm Recurrence, LocalPatient SelectionTissue and Organ ProcurementTreatment OutcomeDeceased donor liver transplantationHepatocellular carcinomaLiving donor liver transplantation

Identifiers

PMID32833221

DOI10.1007/s12029-020-00481-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.